Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy(ESAWAAPT)

PHASE4CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

November 22, 2020

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
CirrhosisSplenectomy; StatusVenous ThrombosisHypertension, Portal
Interventions
DRUG

Apixaban

From postoperative day 3, patients will receive oral Apixaban 2.5mg bid for six months.

DRUG

Warfarin

From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for six months.

DRUG

Aspirin

From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for six months.

DRUG

Dipyridamole

From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.

DRUG

Low molecular weight heparin

From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.

Trial Locations (1)

225001

Clinical Medical College of Yangzhou University, Yangzhou

All Listed Sponsors
lead

Northern Jiangsu People's Hospital

OTHER

NCT04645550 - Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy(ESAWAAPT) | Biotech Hunter | Biotech Hunter